Male fertility depends on a signaling chain that starts in the brain: the hypothalamus releases a signal that prompts the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which in turn instruct the testes to produce testosterone and sperm. When that chain is interrupted at the pituitary or hypothalamic level, a condition called hypogonadotropic hypogonadism, the testes receive no signal at all, even though they remain structurally capable of responding to one.
This is the clinical scenario where hCG becomes relevant. Because its molecular structure closely resembles luteinizing hormone, it can bind the same receptor on testicular Leydig cells and effectively substitute for the missing pituitary signal.
HCG and luteinizing hormone share the same receptor, LHCGR, on Leydig cells in the testes. When hCG binds that receptor, it stimulates those cells to produce testosterone in much the same way natural LH would, which is the basis for its use in men whose own LH output is insufficient.
This receptor-sharing relationship is explored in more depth in our article comparing hCG and LH directly, including why hCG is favored in clinical settings over synthetic LH itself.
One practical reason hCG rather than synthetic LH became the standard clinical tool is its longer persistence in the bloodstream, which allows for a steadier stimulatory signal to reach the testes over time. This pharmacological property, not any difference in what the two hormones do once bound to the receptor, is what makes hCG the more practical choice in real-world treatment settings.
A related clinical use involves men on long-term testosterone replacement therapy. Exogenous testosterone suppresses the natural hypothalamic-pituitary-testicular axis, which can shrink testicular volume and reduce sperm production over time. In men who wish to preserve fertility while still receiving testosterone therapy, physicians may incorporate hCG into the treatment plan specifically because it keeps the testes active independent of the suppressed pituitary signal.
The clinical decision of whether, and how, to use hCG in this context is individualized by the treating physician based on hormone panels, fertility goals, and overall health, and is never a matter of self-directed dosing.
Everywhere hCG is used for male fertility, it is administered under direct physician supervision, with treatment plans built around laboratory monitoring of hormone levels and semen parameters. This is fundamentally different from unsupervised use, a distinction explored in our article on the legal risks of off-label bodybuilding use of hCG.
In the UAE specifically, hCG for any indication, including male fertility, is a prescription-only pharmaceutical regulated by the Ministry of Health and Prevention, discussed further in our overview of hCG regulatory status.
REVIVE LAB UAE supplies non-prescription research peptides intended for laboratory and research applications. HCG, as a regulated fertility and endocrine pharmaceutical, falls outside that scope entirely and is not sold, stocked, or supplied by REVIVE LAB UAE in any form.